Articles tagged "Graft arterlosclerosis"

2015 American Transplant Congress
Dietary-Associated Trimethylamine N-Oxide (TMAO) Levels Is associated With Coronary Allograft Vasculopathy Following Heart Transplantation
S. Zeltzer,¹ Z. Wang,¹ M. Askar,² J. Coughlin,¹ T. Hudec,¹ D. Taylor,³ L. Li,¹ R. Starling,³ S. Hazen,¹ W. Tang.¹
¹Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH; ²Transplant Center, Cleveland Clinic, Cleveland, OH; ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.
Background: Coronary allograft vasculopathy (CAV) is a leading cause of cardiac graft failure after 1 year post transplant. It is characterized by an inflammatory vascular…
2015 American Transplant Congress
Endosome-Based Activation of Non-Canonical NF-kB Signaling By Membrane Attack Complexes
D. Jane-wit,¹ Y. Surovtseva,² L. Qin,³ P. Clark,⁴ T. Manes,⁴ M. Kashgarian,⁵ N. Kirkiles-Smith,⁴ R. Liu,⁴ C. Wang,⁴ G. Tellides,³ J. Pober.⁴
¹Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT; ²Yale Center for Molecular Discovery, Yale University School of Medicine, New Haven, CT; ³Department of Surgery, Yale University School of Medicine, New Haven, CT; ⁴Department of Immunobiology, Yale University School of Medicine, New Haven, CT; ⁵Department of Pathology, Yale University School of Medicine, New Haven, CT.
Using sera from transplant patients with high-titer panel reactive antibody (PRA), we previously described a model for studying the effects of alloantibody binding and complement…
2015 American Transplant Congress
Oxidative Stress During Organ Recovery Influences Transplant Vasculopathy Development
M. Maglione,¹ G. Riede,¹ B. Cardini,¹ D. Bernhard,² B. Messner,² K. Watschinger,³ C. Steger,⁴ G. Brandacher,⁵ J. Pratschke,¹ E. Werner,³ R. Oberhuber.¹
¹Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria; ²Cardiac Surgery Research Laboratory, Department of Surgery, Vienna Medical University, Vienna, Austria; ³Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria; ⁴Institute of Pathology, Innsbruck Medical University, Innsbruck, Austria; ⁵Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Transplant vasculopathy is still a major obstacle to long-term graft survival. Pharmacological strategies aiming at preventing it are still lacking. Herein we show that the…
2015 American Transplant Congress
Is There a Protective Value for Low Level Donor Specific Antibodies to Prevent Cardiac Allograft Vasculopathy After Heart Transplant?
M. Kittleson, J. Patel, F. Liou, S. Siddiqui, J. Yabuno, D. Chang, D. Ramzy, L. Czer, F. Esmailian, N. Reinsmoen, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Donor specific antibodies (DSA) following heart transplant has been reported to be associated with increased development of cardiac allograft vasculopathy (CAV) and risk of…
2015 American Transplant Congress
Long-Term Results After Heart Transplantation – A Randomized Trial Comparing Tacrolimus Versus Cyclosporine A in Combination With Mycophenolate Mofetil After a Mean Duration of 15 Years
S. Guethoff,¹ C. Grinninger,¹ B. Reichart,² P. Ueberfuhr,¹ C. Hagl,¹ B. Meiser.²
¹Department of Cardiac Surgery, Ludwig-Maximilians University, Munich, Germany; ²Transplantation Center, Ludwig-Maximilians University, Munich, Germany.
Purpose. Development of cardiac allograft vasculopathy (CAV), renal dysfunction and malignancies are the main risks due to long-term immunosuppressive therapy after heart transplantation (HTx). We…